

## UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/763,904	01/23/2004	Pascal Druzgala	ARYX-101XCD2	7766
20306 75	00 05/12/2005		EXAMINER	
MCDONNEL	L BOEHNEN HULBE	BALASUBRAMANIAN, VENKATARAMAN		
300 S. WACKE 32ND FLOOR	ER DRIVE		ART UNIT	PAPER NUMBER
CHICAGO, IL			1624	

DATE MAILED: 05/12/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
		10/763,904	DRUZGALA ET AL.			
	Office Action Summary	Examiner	Art Unit			
		Venkataraman Balasubramanian	1624			
Period fo	The MAILING DATE of this communication ap or Reply	opears on the cover sheet with the c	orrespondence address			
THE I - Exter after - If the - If NO - Failu Any	ORTENED STATUTORY PERIOD FOR REP MAILING DATE OF THIS COMMUNICATION asions of time may be available under the provisions of 37 CFR 1 SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a reperiod for reply is specified above, the maximum statutory period reto reply within the set or extended period for reply will, by statutely received by the Office later than three months after the mailed patent term adjustment. See 37 CFR 1.704(b).	.136(a). In no event, however, may a reply be timely within the statutory minimum of thirty (30) dayed will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).			
Status						
1)	Responsive to communication(s) filed on <u>02</u>	March 2005.	•			
· · ·	·	is action is non-final.				
3)	, <del></del>					
,	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposit	ion of Claims					
4)[🖂	Claim(s) 2-8 is/are pending in the application	l.				
•	4a) Of the above claim(s) is/are withdrawn from consideration.					
	Claim(s) is/are allowed.					
	Claim(s) <u>2-8</u> is/are rejected.					
·	Claim(s) is/are objected to.					
·	Claim(s) are subject to restriction and	or election requirement.				
Applicati	ion Papers					
9)	The specification is objected to by the Examin	ner.				
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority (	under 35 U.S.C. § 119					
•	Acknowledgment is made of a claim for foreig	on priority under 35 U.S.C. & 119/a	)-(d) or (f).			
	☐ All b)☐ Some * c)☐ None of: 1.☐ Certified copies of the priority docume	nts have been received.	•			
	2. Certified copies of the priority docume	• •				
	3. Copies of the certified copies of the pri	•	ed in this National Stage			
* 6	application from the International Bure	• • • • • • • • • • • • • • • • • • • •	d			
·· <b>`</b>	See the attached detailed Office action for a lis	st or the certified copies not receive	ea.			
Am 1	M-)					
Attachmen		A) T Interview Summer	(PTO-413)			
1) Motice of References Cited (PTO-892)  4) Interview Summary (PTO-413)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  Paper No(s)/Mail Date.						
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  Paper No(s)/Mail Date  5) Notice of Informal Patent Application (PTO-152)  Other:						

Art Unit: 1624

## **DETAILED ACTION**

Applicants' response, which included cancellation of claim 1 and addition of new claims 2-8, filed on 3/2/2005, is made of record. Claims 2-8 are now pending.

In view of applicants' response, the following rejections apply.

## **Double Patenting**

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 2-8 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 21-36 of U.S. Patent No. 6,387,914. Although the conflicting claims are not identical, they are not patentably distinct from each other because the compound and composition embraced in instant claims 2-8 are also embraced in the claims 21-36 of US 6,387,914.

US 6,387,924 teaches several barbiturate compounds and pharmaceutical composition, which include compounds generically claimed in the instant claims. See formula I, Formula II in claim 21, and note the definition of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, X<sub>1</sub>,

Art Unit: 1624

 $X_2$  and  $X_3$ . Note with given definition of these variable groups, the compounds and composition taught in US 6,387, 914 include instant compounds and their composition.

Thus it would have been obvious to one having ordinary skill in the art at the time of the invention was made to make compounds variously substituted in barbiturate compounds as permitted by the reference and expect resulting compounds (instant compounds) to possess the uses taught by the art in view of the equivalency teaching outline above.

Claims 2-8 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 15-26 of U.S. Patent No. 6,685,086. Although the conflicting claims are not identical, they are not patentably distinct from each other because the compound and composition embraced in instant claims 2-8 are also embraced in the claims 15-26 of US 6,685,086.

US 6,685,086 teaches several barbiturate compounds and pharmaceutical composition, which include compounds generically claimed in the instant claims. See formula I, Formula II in claim 15 and 21, and note the definition of  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$ ,  $R_6$ ,  $R_7$ ,  $X_1$ ,  $X_2$  and  $X_3$ . Note with given definition of these variable groups, the compounds and composition taught in US 6,685,086 include instant compounds and their composition.

Thus it would have been obvious to one having ordinary skill in the art at the time of the invention was made to make compounds variously substituted in barbiturate compounds as permitted by the reference and expect resulting compounds (instant

Art Unit: 1624

compounds) to possess the uses taught by the art in view of the equivalency teaching outline above.

## Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication from the examiner should be addressed to Venkataraman Balasubramanian (Bala) whose telephone number is (571) 272-0662. The examiner can normally be reached on Monday through Thursday from 8.00 AM to 6.00 PM. The Supervisory Patent Examiner (SPE) of the art unit 1624 is Mukund Shah whose telephone number is (571) 272-0674. If Applicants are unable to reach Mukund Shah within 24-hour period, they may contact James O. Wilson, Acting-SPE of art unit 1624 at 571-272-0661.

Art Unit: 1624

The fax phone number for the organization where this application or proceeding

Page 5

is assigned (703) 872-9306. Any inquiry of a general nature or relating to the status of

this application or proceeding should be directed to the receptionist whose telephone

number is (571) 272-1600.

Information regarding the status of an application may be obtained from the

Patent Application Information Retrieval (PAIR) system. Status information for published

applications may be obtained from either Private PAIR or Public PAG. Status

information for unpublished applications is available through Private PAIR only. For

more information about the PAIR system, see http://pair-direct.uspto.gov. Should you

have questions on access to the Private PAIR system, contact the Electronic Business

Center (EBC) at 866-2 17-9197 (toll-free).

Venkataraman Balasubramanian

5/7/2005